Eli Lilly and Company (LLY)vsSagimet Biosciences Inc. Series A Common Stock (SGMT)
LLY
Eli Lilly and Company
$1,170.45
+0.45%
HEALTHCARE · Cap: $994.92B
SGMT
Sagimet Biosciences Inc. Series A Common Stock
$11.09
+2.69%
HEALTHCARE · Cap: $676.29M
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 33.5% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
SGMT
Avoid28
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 30.8x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : SGMT
The strongest argument for SGMT centers on Debt/Equity, Price/Book.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : SGMT
The primary concerns for SGMT are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
LLY profiles as a growth stock while SGMT is a value play — different risk/reward profiles.
SGMT carries more volatility with a beta of 3.49 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 28/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Sagimet Biosciences Inc. Series A Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Sagimet Biosciences Inc. (SGMT) is an innovative biotechnology company focused on developing breakthrough treatments for metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). The company is actively advancing its lead therapeutic candidate through various clinical trial phases, employing cutting-edge mechanisms designed to enhance patient outcomes. Backed by a robust management team and a strong intellectual property portfolio, Sagimet is strategically positioned to capitalize on the growing market demand for effective metabolic disease therapies, making it an attractive investment proposition for institutional investors in the dynamic biotech sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?